MedSci Healthcare Holdings Limited provided consolidated earnings guidance for the year ended December 31, 2023. For the period, the Group is expected to record a profit attributable to the Shareholders of not less than RMB 50 million for the year ended 31 December 2023 as compared to a net loss attributable to the Shareholders recorded for the year ended 31 December 2022. The profit turnaround of the Group was mainly attributable to the following: (i) against the backdrop of anti-corruption measures in medical industry, doctors became more career-focused, at the same time, pharmaceutical and medical device companies began to transform their existing marketing models, enabling the Company to expand its business scale; (ii) enhancement of application of artificial intelligence within the Group which improved its production efficiency; and (iii) fair value gain on convertible redeemable preferred shares.